[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: ADG20 (fully human monoclonal immunoglobulin G (IgG)1 antibody IM): Route of administration: Participants will receive a single dose of ADG20 as Intramuscular injection on Day 1.Duration of therapy: AfterDay 1; participants will then be followed via telemedicine visits; phone calls; or in-person visitsthrough Month 14 as indicated in the Schedule of AssessmentsDose : ADG20 300 mg IMControl Intervention1: Placebo IM: Placebo IM (matching volume of Intramuscular Injection 300 mg of ADG20)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: ADG20 (fully human monoclonal immunoglobulin G (IgG)1 antibody IM): Route of administration: Participants will receive a single dose of ADG20 as Intramuscular injection on Day 1.Duration of therapy: AfterDay 1; participants will then be followed via telemedicine visits; phone calls; or in-person visitsthrough Month 14 as indicated in the Schedule of AssessmentsDose : ADG20 300 mg IM", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Placebo IM: Placebo IM (matching volume of Intramuscular Injection 300 mg of ADG20)", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 597, "treatment_name": "Human immunoglobulin", "treatment_type": "Immunoglobulins", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]